Published in Cancer Weekly, December 23rd, 2003
The results were presented in a poster entitled "A phase I study of a second-generation immunomodulatory oligonucleotide (HYB2055) in patients with advanced solid malignancies" at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts. IMOxine is a novel immunomodulatory oligonucleotide constructed with two immunostimulatory motifs joined via a 3'-3'...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.